ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS

Summary

This randomized controlled trial was conducted at the Department of Medicine and Diabetes of Mayo Hospital/King Edward Medical University, Lahore, over one year. A total of 80 patients with type 2 diabetes and normal serum uric acid were randomly assigned to two groups: Group A received allopurinol with lisinopril, and Group B received lisinopril alone. Patients were monitored every three months for serum creatinine, spot urine albumin, and serum uric acid levels. The primary endpoint was a \>300 mg/L increase in urine albumin from baseline. Blood pressure was managed with agents other than ACE inhibitors if required.

Timeline

Start

2023-05-14

Primary completion

2024-09-23

Completion

2024-11-18

Publications

• Background Robinson RL, et al. Allopurinol reduces proteinuria in diabetic nephropathy: A randomized controlled trial. Diabetologia. 2020;63(6):1217-1224.

Drugs

Indications